Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); Combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 42.e13-42.e19

  Ding, Weihong ^a   Gou, Yuancheng ^a   Sun, Chuanyu ^a   Xia, Guowei ^a   Wang, Hong ^a   Chen, Zhongqing ^a   Tan, Jun ^a   Xu, Ke ^a   Qiang, Ding ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

EORTC; Immunohistochemistry; Ki 67; Non muscle invasive bladder cancer; Prognosis

Indexed keywords

MONOCLONAL ANTIBODY KI 67;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RISK FACTOR; TRANSURETHRAL RESECTION; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT;

EORTC; IMMUNOHISTOCHEMISTRY; KI-67; NON-MUSCLE INVASIVE BLADDER CANCER; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 85027087863     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.05.004     Document Type: Article

References (24)

1. Parkin M.D., Bray F., Ferlay J., et al. Global Cancer Statistics, 2002. CA Cancer J Clin 2005, (55):74-108.
2. Babjuk Marko, Oosterlinck Willem, Sylvester Richard, et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011, (59):997-1008.
3. Kurth K.H., Denis L., Bouffioux C., Sylvester R., Debruyne F.M.J., Pavone-Macaluso M., et al. Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer 1995, 31A:1840-1846.
4. Allard P., Bernard P., Fradet Y., Tetu B. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 1998, 81:692-698.
5. Soloway M.S. It is time to abandon the "superficial" in bladder cancer. Eur Urol 2007, 52:1564-1565.
6. Bryan R.T., Wallace D.M. "Superficial" bladder cancer-time to uncouple pT1 tumours from pTa tumours. BJU Int 2002, 90:846-852.
7. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49:466-477.
8. Sylvester Richard J. how well can you actually predict which non-muscle-invasive bladder cancer patients will progress?. Eur Urol 2011, 60:431-434.
9. Cattoretti G., Becker M.H., Key G., et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992, 168(4):357-363.
10. Scholzen T., Gerdes J. The ki-67 protein: from the known and the unknown. J cell Physiol 2000, 182:311-322.
11. Popov Z., Hoznek A., Colombel M., et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 1997, 80:1472-1481.
12. Liukkonen T., Rajala P., Raitanen M., Rintala E., Kaasinen E., Lipponen P. Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group. Eur Urol 1999, 36:393-400.
13. Pfister C., Lacombe L., Vezina M.C., et al. Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors. Hum Pathol 1999, 30:1350-1355.
14. Wu T.T., Chen J.H., Lee Y.H., Huang J.K. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000, 163:758-760.
15. Margulis V., Lotan Y., Karakiewicz P.I., et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J. Natl Cancer Inst 2009, 101:114-119.
16. Greene F.L., Page D.L., Fleming I.D., et al. AJCC Cancer Staging Manual 2002, Springer Verlag, New York. 6th ed.
17. Mostofi F.K., Sobin L.H., Torloni H. Histological typing of urinary bladder tumours. International Histological Classification of Tumors 1973, 10. World Health Organization, Geneva.
18. van Rhijn B.W., Vis A.N., van der Kwast T.H., et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003, 21:1912-1921.
19. Dybowski B., Kupryjańczyk J., Rembiszewska A., Pykało R., Borkowski A. P27(kip1) and ki-67 expression analysis in transitional cell carcinoma of the bladder. Urol Res 2003, 31:397-401.
20. Pich A., Chiusa L., Formiconi A., et al. Proliferative activity is the most significant predictor of recurrence in non-invasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer 2002, 15:784-790.
21. van Oers J.M., Wild P.J., Burger M., et al. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol 2007, 52:760-768.
22. van Rhijn B.W., Zuiverloon T.C., Vis A.N., et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010, 58:433-441.
23. Bertz S, Otto W, Denzinger S, et al. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Eur Urol 2012 <>[j.eururo.2012.05.033]. http://dx.doi.org/10.1016/.
24. Schrier B.P., Hollander M.P., van Rhijn B.W.G., Kiemeney L.A., Witjes J.A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumors and implications for therapy. Eur Urol 2004, 45:292-296.